Quantitative Investment Management LLC Buys Shares of 198,699 Novo Nordisk A/S $NVO

Quantitative Investment Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 198,699 shares of the company’s stock, valued at approximately $11,025,000. Novo Nordisk A/S makes up 1.5% of Quantitative Investment Management LLC’s portfolio, making the stock its 15th biggest position.

A number of other institutional investors have also made changes to their positions in the business. Beacon Financial Group increased its stake in Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC grew its holdings in shares of Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after acquiring an additional 200 shares in the last quarter. SeaBridge Investment Advisors LLC increased its position in shares of Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after acquiring an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC increased its position in shares of Novo Nordisk A/S by 1.0% in the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 200 shares during the last quarter. Finally, Revolve Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on NVO. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. Citigroup initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $49.93.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks upgraded Novo Nordisk from “strong sell” to “hold,” a modest vote that may limit further downside from some retail/quant sellers. Read More.
• Positive Sentiment: Novo entered a WHO Foundation partnership focused on cardio‑renal‑metabolic diseases and committed funding for obesity/diabetes efforts in low‑ and middle‑income countries — a reputational and long‑term access play that supports the company’s global public‑health positioning. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results showing income and investment returns; while the report is routine, its figures are being viewed through the lens of Novo Nordisk’s share‑price swing. Read More.
• Neutral Sentiment: India’s regulator warned drugmakers about direct or surrogate advertising for weight‑loss drugs, a policy development that adds regulatory complexity across a large and fast‑growing market but is industry‑wide rather than Novo‑specific. Read More.
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide, triggering immediate regulatory risk and heightened compliance scrutiny that can hurt investor confidence and valuation. Read More.
• Negative Sentiment: Regulatory news sparked sharp market reaction and legal attention: a class‑action/investor probe (Pomerantz) was announced and some articles report a very steep intraday drop tied to the FDA news, increasing the chance of litigation and reputational/financial fallout. Read More.
• Negative Sentiment: Analysts have reacted: TD Cowen and others trimmed ratings/targets, and coverage notes the hit to Novo Holdings’ controlling‑shareholder asset value — both amplify selling pressure. Read More.
• Negative Sentiment: Competitive pressure from Eli Lilly (big investments and programs to expand GLP‑1 access) is a strategic negative for Novo’s long‑term market share and pricing power in GLP‑1s. Investors should factor stronger Lilly initiatives into longer‑term growth forecasts. Read More.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $38.04 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average price is $50.43 and its two-hundred day moving average price is $51.92. The company has a market cap of $169.83 billion, a PE ratio of 10.96 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.